Preparation method of silicon-nanowire-based medicinal carrier

Abstract

The invention discloses a preparation method of a silicon-nanowire-based medicinal carrier. The method comprises the following steps of: preparing a system of between 20 and 200mg / ml from the silicon nanowire with buffer; adding an antitumor medicament to obtain mixed liquid; oscillating for 3 to 30 hours at a temperature of between 20 and 37 DEG C; centrifuging, and washing with the same buffer for 3 to 10 times; and removing the antitumor medicament which is not combined on the upper layer to obtain the lower precipitate, which is silicon nanowire-antitumor medicinal composition. According to the method, the load efficiency of a traditional antitumor medicament in a carrier can be greatly improved along with safe operation, quickness and convenience; and the obtained silicon nanowire-antitumor medicinal composition can play an excellent role in killing cancer cells on cell and living body levels, and plays an effect of medicament sustained release, so that tumor growth can be inhibited in a long time. The silicon-nanowire-based medicinal carrier can be used as a nano-medicament due to the great loading efficiency of the silicon nanowire, and can be widely applied to the field of cancer treatment.

Description

technical field

[0001] The invention belongs to the technical field of nanometer biomedicine, and relates to a preparation method of a nanomaterial drug carrier, in particular to a preparation method of a silicon nanowire-based drug carrier. Background technique

[0002] With the rapid development of nanobiotechnology, nanomaterials as drug carriers for cancer therapy have received extensive attention in recent years. Traditional anticancer drugs, such as doxorubicin hydrochloride (DOX) and paclitaxel (PTX), will be distributed in normal tissues and can be quickly cleared by the kidneys, and only a very small amount of anticancer drugs can accumulate in the cancer site to play a role ( Clin.Cancer.Res.1999,5,1703-1707;Pharm.Res.2003,20,1337-1350;Clin.Cancer.Res.2005,11,8782-8788;Nat.Rev.Cancer. 592.), thus being greatly limited in cancer treatment.

[0003] In order to increase the drug concentration of antitumor drugs at the site of action, one of the effective strategies...

Images